Cleveland Skin Pathology
Share
At that time, he was Chairman of the Department of Dermatology at MetroHealth Medical Center in Cleveland, Ohio and an Associate Professor of Dermatology and Pathology at Case Western Reserve University School of Medicine. Highly respected by his colleagues, who often sought his expert opinion on cutaneous disease, he recognized the need for an independent laboratory solely dedicated to diagnosing
07/20/2015
Our laboratory has received accreditation from the College of American Pathologists.
09/25/2014
Visit our website:
http://clevelandskinpathology.com
ClevelandSkinPathology.com We understand that diagnosing a skin biopsy is only part of what you need from a dermatopathology lab. Our team is made up of dermatologists with active academic and clinical practices.
CLEVELAND SKIN PATHOLOGY CHOSEN FOR NOVEL MELANOMA ASSAY!
A new clinically validated RNA-based diagnostic test myPath ™ Melanoma is now available from Myriad Genetic Laboratories to aid in the diagnosis of melanocytic lesions as being benign or malignant.
It is well known that melanoma is highly curable if diagnosed and treated in early stages. There is a marked difference in survival between localized and metastatic disease. Therefore, diagnostic markers that facilitate accurate diagnosis of melanoma at earlier stages could help prevent progression of the disease and reduce patient mortality. The myPath™ Melanoma assay features 23 unique molecular biomarkers whose gene expression profile has been shown to differentiate benign lesions from malignant melanoma with high sensitivity and specificity in multiple independent cohorts.
The development and training of the assay was conducted on 464 melanocytic lesions consisting of all major histological subtypes1. The assay was validated in a second cohort, with a total of 437 melanocytic lesions, also consisting of all major histological subtypes. In this validation study, the assay had a sensitivity of 90% and specificity of 91%.
A small group of dermatopathologists have been selected to have exclusive access to this test at no cost to the patient, physician, lab or third party payor for a limited time prior to the test being widely available. Cleveland Skin Pathology Laboratory has been selected as a test site and we wanted you to know that we may order this test on your patient, if appropriate (within the intended use) for the diagnostic process. If you would like more information or would like to obtain this test on a specific patient, please contact any of our pathologists and we will make arrangements to have the case sent to Myriad.
1 Clarke L et al. American Society of Dermatopathology 50th Annual Meeting. 2013.
Additional information available at www.Myriad.com or www.IsThisMelanoma.com
Click here to claim your Sponsored Listing.
